Dinamika pendapatan YoY sajrone rolas wulan kepungkur: Harrow, Inc. (HROW)

The revenue trend over four quarters year-over-year confirms profits from the sale of innovative ophthalmological products and glaucoma therapies for Harrow, Inc. (HROW). An expanding patient base and FDA approvals are developing the distribution ecosystem. Market leadership status and customized medications ensure high margins and stable FCF. The value of 21.50 represents the current metric, capturing the final point of annual sales dynamics.
Harrow - rincian analitis lan metrik utama (HROW)

To identify fundamental value drivers, it is essential to analyze the annual revenue growth rate (rolling period), which measures the percentage change in revenue over the last 12 months relative to the previous year. This trend reflects the effectiveness of the expansion of Harrow, Inc. (HROW) within the ophthalmology pharmaceutical segment and the demand for its specialized pharmacy centers among physicians in the US.